The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children

NCT ID: NCT02301650

Last Updated: 2014-11-26

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 400 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2017-12-31

Brief Summary

Mother to child transmission(MTCT) is the main route of hepatitis B virus(HBV) transmission.High HBV DNA level of pregnant women is the main risk factor of MTCT. Many literatures demonstrate that using nucleoside (acid) analogs in late pregnancy can significantly reduce HBV DNA level and effectively blocking MTCT. Therefore, treatment guidelines of hepatitis B in Europe and the Asia Pacific region clearly pointed out: Nucleoside (acid) analogs can be used in pregnant women after 28 weeks of gestation for blocking MTCT in mothers with high HBV DNA level. At present, the drugs used in late pregnancy including lamivudine (LAM) ,telbivudine(LdT) and tenofovir(TDF).

The safety of nucleoside (acid) analogues used in late pregnancy on children is not clear.In most of the related researches,the observation termination was 7-12 months after birth, and most were concentrated on the blocking effect of MTCT.The long-term impact of Nucleoside (acid) analogues on children's development has not been reported in the literatures. The aim of this study is to make clear of the effect of nucleoside (acid) analogues used in late pregnancy on long-term impact of children's development.

The one year old children born in Beijing Ditan hospital and whose mothers had taken LAM,LdT or TDF during late pregnancy will be enrolled as study group, and eligible children whose mothers untreated will be enrolled as control group. The children's height, weight, nutritional status, developmental quotient and immune response to hepatitis B vaccine etc will be evaluated at baseline and at 3 years old. By comparing the children's development in different groups as well as in self-control of different ages, we will discuss the effect of Nucleoside (acid) analogues on children's long-term development.

Conditions

the Safety of Anti-viral Drugs Used in Late Pregnancy

Keywords

Hepatitis B virus; pregnancy; nucleoside (acid) analogs; children; safety

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

group A

The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy

Lamivudine

Intervention Type: DRUG

mothers use Lamivudine in late pregnancy

group B

The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy

Telbivudine

Intervention Type: DRUG

mothers use Telbivudine in late pregnancy

group C

The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy

Tenofovir

Intervention Type: DRUG

mothers use Tenofovir in late pregnancy

group D

The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy

No interventions assigned to this group

Interventions

Lamivudine

mothers use Lamivudine in late pregnancy

Intervention Type: DRUG

Telbivudine

mothers use Telbivudine in late pregnancy

Intervention Type: DRUG

Tenofovir

mothers use Tenofovir in late pregnancy

Intervention Type: DRUG

Other Intervention Names

3-TC; CAS: 134678-17-4; CAS: 3424-98-4; Tenofovir Disoprox; CAS: 147127-20-6

Eligibility Criteria

Inclusion Criteria

• The one year old children whose mothers had taken Lamivudine,Telbivudine or Tenofovir in late pregnancy(28-30 weeks of gestation);
• The one year old children whose mothers untreated in late pregnancy;
• Children had completed standard hepatitis B vaccine and hepatitis B immune globulin combined active and passive prophylaxis;
• HBV DNA level of the children's mothers were over 6.0 log10 IU/ml before 28 weeks of gestation.

Exclusion Criteria

• Children whose mothers over 35 years old at delivery;
• The couple having family hereditary disease or abnormal malformation has been found at fetal screening before 28 weeks gestation;
• History of amniocentesis during pregnancy;
• Co-infection with either hepatitis C virus, hepatitis D virus, human immunodeficiency virus, syphilis, toxoplasmosis, rubella or cytomegalovirus.
• Complications of pregnancy-induced hypertension, premature rupture of membranes, preterm birth, placenta previa or placental abruption; asphyxia at birth.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 3 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Ditan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Wei Yi

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Wei Yi

Role: PRINCIPAL_INVESTIGATOR

Beijing Ditan Hospital

Other Identifiers

Z141107002514131

Identifier Type: -

Identifier Source: org_study_id